Search
for
Sort by
Research 301–330 of 1000+
- Scarring hair follicle destruction is driven by the collapse of EGFR-protected JAK-STAT1-sensitive stem cell immune privilege
- Criteria for Commencing and Continuing Subsidised Janus Kinase Inhibitor Therapy in Australian Alopecia Areata Patients—Results From an Australian Expert Consensus Exercise
- The Relative Efficacy and Safety of Monotherapies for Alopecia Areata: A Network Meta‐Analysis Study
- Association of Janus kinase inhibitors with reduced depression in alopecia areata
- JAK Inhibitors in Down Syndrome: Alopecia Areata Resolution and Vitiligo Improvement with Baricitinib
- Exploring the efficacy of baricitinib in treating alopecia areata after failed Janus kinase inhibitor therapy
- A Discrete Choice Experiment of Clinician Preferences Among Attributes of Approved Janus Kinase Inhibitors for Alopecia Areata
- Baricitinib Effectiveness in JAKi‐Naïve and Tofacitinib‐Exposed Patients: A Prospective Study in Alopecia Areata
- 691 Topical curcumin promotes induction of the murine hair cycle
- Patient preferences for treatment characteristics of Janus kinase inhibitors for alopecia areata: a discrete choice experiment
- Title Choice of treatment for severe forms of alopecia areata (case reports)
- Successful treatment of resistant alopecia totalis with tofacitinib
- The Burden of Alopecia Areata and Management with Baricitinib in the United Arab Emirates: A Narrative Review
- JAK1 Signaling Is Involved in the Induction of Mechanical Alloknesis in Atopic Dermatitis
- 695 Selectively targeting JAK1 or JAK3 pathway is sufficient to reverse alopecia areata
- Public Interest in Janus Kinase (JAK) IInhibitors for Alopecia Areata: A Google Trend Analysis
- Screening for latent infectious disease in patients with alopecia areata before initiating JAK inhibitors therapy: a single-center real-world retrospective study
- Ruxolitinib 1.5% Topical Cream for the Treatment of Pediatric Alopecia Areata
- Systemic Inflammation Marker Alterations in Severe Alopecia Areata Patients Treated with Janus Kinase Inhibitors
- A clinical case of familial alopecia areata in combination with immune pathology
- Characterizing Lipid Changes and Use of Lipid-Lowering Medications in Patients With Alopecia Areata Treated With Baricitinib: Integrated Results From the BRAVE-AA1 and -AA2 Clinical Trials
- Experience in treating multifocal alopecia areata in a child with Jak kinase inhibitors
- USE OF TOFACITINIB IN DIFFICULT TO TREAT CLINICALLY AMYOPATHIC DERMATOMYOSITIS
- Case Report: Reversal of Long-Standing Refractory Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus Following Treatment With Tofacitinib
- JAK Family Expression and Therapeutic Implications in Primary Cicatricial Alopecias
- A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata
- Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata
- Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata
- 33766 Efficacy of baricitinib in patients with various degrees of alopecia areata severity: Results from BRAVE-AA1 and BRAVE-AA2
- Off‐Label Use of Topical Ruxolitinib in Dermatology: A Systematic Literature Review and Current Perspectives